PET2 -driven de-escalation therapy in 64 high-risk Hodgkin Lymphoma patients treated with escalated BEACOPP

Benedicte Deau; Patricia Franchi; Josette Briere; Jessica Ohnona; Jerome Tamburini; Catherine Thieblemont; Pauline Brice

doi:10.1111/bjh.13287

PET2 -driven de-escalation therapy in 64 high-risk Hodgkin Lymphoma patients treated with escalated BEACOPP

Br J Haematol. 2015 Jul;170(2):278-81. doi: 10.1111/bjh.13287. Epub 2015 Jan 9.

Authors

Benedicte Deau^{1

2}, Patricia Franchi³, Josette Briere⁴, Jessica Ohnona⁵, Jerome Tamburini^{6

7}, Catherine Thieblemont³, Pauline Brice³

Affiliations

¹ Haematology Department, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. benedicte.deau-fischer@cch.aphp.fr.
² Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France. benedicte.deau-fischer@cch.aphp.fr.
³ Department of Haematology, Hôpital Saint Louis, Paris, France.
⁴ Department of Histopathology, Hôpital Saint Louis, Paris, France.
⁵ Department of Nuclear Medicine, Hôpital Saint Louis, Paris, France.
⁶ Haematology Department, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
⁷ Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.

PMID: 25580881
DOI: 10.1111/bjh.13287

No abstract available

Keywords: (BEACOPP) Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Hodgkin; Oncovin; Prednisone; Procarbazine; lymphoma; positron emission tomography/computerized tomography scan.

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bleomycin / therapeutic use
Cyclophosphamide / therapeutic use
Doxorubicin / therapeutic use
Etoposide / therapeutic use
Hodgkin Disease / diagnosis*
Hodgkin Disease / drug therapy*
Humans
Neoplasm Staging
Positron-Emission Tomography*
Prednisone / therapeutic use
Procarbazine / therapeutic use
Treatment Outcome
Vincristine / therapeutic use

Substances

Bleomycin
Procarbazine
Vincristine
Etoposide
Doxorubicin
Cyclophosphamide
Prednisone

Supplementary concepts

BEACOPP protocol